Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 ?-chain, dimer
HER2-negative Breast Cancer
QuantumLeap Healthcare Collaborativemonoclonal_antibodyPhase 2Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 31/ 100
- Competitive Position
- 65/ 100
Competitive context
191 Active assets in the HER2-negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Palbociclib Helwan University | Phase 2 | BBB |
EXEMESTANE National Cancer Institute (NCI) | Phase 4 | BBB |
Pembrolizumab UNC Lineberger Comprehensive Cancer Center | Phase 2 | BBB |
Atezolizumab TransThera Sciences (Nanjing), Inc. | Phase 2 | BB |
Inno-206 Roswell Park Cancer Institute | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 ?-chain, dimer is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →